Inhibition of PI3K suppresses propagation of drug-tolerant cancer cell subpopulations enriched by 5-fluorouracil.

Ishida, Kaoru; Ito, Chie; Ohmori, Yukimi; Kume, Kohei; Sato, Kei A; Koizumi, Yuka; Konta, Akari; Iwaya, Takeshi; Nukatsuka, Mamoru; Kobunai, Takashi; Takechi, Teiji; Nishizuka, Satoshi S

Ishida, Kaoru; Ito, Chie; Ohmori, Yukimi; Kume, Kohei; Sato, Kei A; Koizumi, Yuka; Konta, Akari; Iwaya, Takeshi; Nukatsuka, Mamoru; Kobunai, Takashi; Takechi, Teiji; Nishizuka, Satoshi S.

Afiliação

Ishida K; Molecular Therapeutics Laboratory, Department of Surgery, Iwate Medical University School of Medicine, Morioka, Iwate, 020-8505, Japan.
Ito C; Molecular Therapeutics Laboratory, Department of Surgery, Iwate Medical University School of Medicine, Morioka, Iwate, 020-8505, Japan.
Ohmori Y; Molecular Therapeutics Laboratory, Department of Surgery, Iwate Medical University School of Medicine, Morioka, Iwate, 020-8505, Japan.
Kume K; Molecular Therapeutics Laboratory, Department of Surgery, Iwate Medical University School of Medicine, Morioka, Iwate, 020-8505, Japan.
Sato KA; Division of Biomedical Research and Development, Institute of Biomedical Science, Iwate Medical University, Morioka, Iwate, 020-8505, Japan.
Koizumi Y; Molecular Therapeutics Laboratory, Department of Surgery, Iwate Medical University School of Medicine, Morioka, Iwate, 020-8505, Japan.
Konta A; Molecular Therapeutics Laboratory, Department of Surgery, Iwate Medical University School of Medicine, Morioka, Iwate, 020-8505, Japan.
Iwaya T; Molecular Therapeutics Laboratory, Department of Surgery, Iwate Medical University School of Medicine, Morioka, Iwate, 020-8505, Japan.
Nukatsuka M; Molecular Therapeutics Laboratory, Department of Surgery, Iwate Medical University School of Medicine, Morioka, Iwate, 020-8505, Japan.
Kobunai T; Translational Research Laboratory, Taiho Pharmaceutical Co., Ltd., Tokushima, Tokushima, 771-0194, Japan.
Takechi T; Translational Research Laboratory, Taiho Pharmaceutical Co., Ltd., Tokushima, Tokushima, 771-0194, Japan.
Nishizuka SS; Translational Research Laboratory, Taiho Pharmaceutical Co., Ltd., Tokushima, Tokushima, 771-0194, Japan.

Sci Rep ; 7(1): 2262, 2017 05 23.

Article em En | MEDLINE | ID: mdl-28536445

Assuntos

Antimetabólitos Antineoplásicos/farmacologia; Resistencia a Medicamentos Antineoplásicos/efeitos dos fármacos; Fluoruracila/farmacologia; Inibidores de Fosfoinositídeo-3 Quinase; Animais; Linhagem Celular Tumoral; Proliferação de Células/efeitos dos fármacos; Classe I de Fosfatidilinositol 3-Quinases/antagonistas & inibidores; Classe I de Fosfatidilinositol 3-Quinases/genética; Classe I de Fosfatidilinositol 3-Quinases/metabolismo; Códon; Modelos Animais de Doenças; Relação Dose-Resposta a Droga; Resistencia a Medicamentos Antineoplásicos/genética; Variação Genética; Xenoenxertos; Humanos; Camundongos; Neoplasias/genética; Neoplasias/metabolismo; Neoplasias/patologia; Fenótipo; Fosfatidilinositol 3-Quinases/genética; Fosfatidilinositol 3-Quinases/metabolismo; Fosforilação; Proteoma; Proteômica/métodos; Proteínas Quinases S6 Ribossômicas 90-kDa/metabolismo; Transdução de Sinais

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Resistencia a Medicamentos Antineoplásicos / Fluoruracila / Inibidores de Fosfoinositídeo-3 Quinase / Antimetabólitos Antineoplásicos Limite: Animals / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google